↓ Skip to main content

Cochrane Database of Systematic Reviews

Tiotropium versus placebo for chronic obstructive pulmonary disease

Overview of attention for article published in this source, July 2012
Altmetric Badge

Mentioned by

1 blog
2 policy sources
8 tweeters
1 Facebook page


96 Dimensions

Readers on

78 Mendeley
Tiotropium versus placebo for chronic obstructive pulmonary disease
Published by
John Wiley & Sons, Ltd, July 2012
DOI 10.1002/14651858.cd009285.pub2
Pubmed ID

Karner, Charlotta, Chong, Jimmy, Poole, Phillippa


Tiotropium is an anticholinergic agent which has gained widespread acceptance as a once daily maintenance therapy for symptoms and exacerbations of stable chronic obstructive pulmonary disease (COPD). In the past few years there have been several systematic reviews of the efficacy of tiotropium, however, several new trials have compared tiotropium treatment with placebo, including those of a soft mist inhaler, making an update necessary.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Chile 1 1%
Italy 1 1%
Unknown 75 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 15 19%
Researcher 13 17%
Student > Postgraduate 10 13%
Other 8 10%
Student > Bachelor 6 8%
Other 22 28%
Unknown 4 5%
Readers by discipline Count As %
Medicine and Dentistry 48 62%
Pharmacology, Toxicology and Pharmaceutical Science 9 12%
Nursing and Health Professions 5 6%
Biochemistry, Genetics and Molecular Biology 3 4%
Social Sciences 2 3%
Other 5 6%
Unknown 6 8%